Dr Jolly is working on multiple clinical trials for novel therapies including gene therapy with a range of institutions. These includes Oxford University, University of Cambridge, and University of Melbourne. From this work Dr Jolly realised that one of the key problems that causes prevention of new therapies from being translated into clinical care is poor choice of outcome measures that means the trials do not meet their objectives. To combat this Dr Jolly’s clinical studies have focused on developing novel and scientifically driven outcome measures that are more fit for purpose. This will combat funding and effort waste and increase success rate of translation for new therapies.

Dr Jolly continually advocates for patients and has led a number of projects to capture their experience of health and participating in scientific research. Patients are not only patients, they are very talented member of society. They are our loved ones, our friends, our colleagues, who all have skills and knowledge we can learn from so workplaces must be made accessible in order to benefit from a wide range of voices and experiences to enhance the work we do.